ClinicalTrials.gg
RecruitingNCT07123103Updated Nov 16, 2026

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of XB371 in Solid Tumors, sponsored by Exelixis. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

02

Conditions studied

  • Solid Tumors

Keywords

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
03

In context

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 to 1.
  • Minimum of ≥ 12 weeks.
  • Recurrent locally advanced or solid tumors.
  • Adequate end organ and bone marrow function.

Key Exclusion Criteria:

  • Primary brain tumors or known active , , or cranial epidural disease.
  • History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
  • Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
  • Known history of immunodeficiency virus () unless specific criteria are met.
  • Active infection with virus (HCV) defined as positive for HCV antibody.
  • Major surgery within 4 weeks before the first dose of study treatment.
  • Received radiation therapy within 2 weeks before the first dose of study treatment.
  • Received prior systemic anticancer therapy including agents within 4 weeks before the first dose of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Dose-escalation Cohorts

    Participants will receive escalating doses of XB371 every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.

    Drug: XB371

  • Experimental
    Dose-expansion Cohorts: Part A

    Participants with Tumor Type 1 (tumor type will be selected based on available data) will be randomized to receive XB371 at one of two recommended dose levels (recommended dose \[RD\]-1 or RD-2) every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.

    Drug: XB371

  • Experimental
    Dose-expansion Cohorts: Part B

    Participants with Tumor Type 2 (tumor type will be selected based on available data) will receive XB371 at the recommended dose level every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.

    Drug: XB371

Interventions

  • DrugXB371

    Intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with a Dose-limiting Toxicity (DLT)

    Time frame: Up to the end of the first cycle (Up to Day 21 of a 21-day cycle)

  2. Number of Participants with a Treatment-emergent Adverse Event (TEAE)

    Time frame: Up to approximately 7 months

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) of XB371, Total Antibody and Unconjugated Belotecan

    Time frame: Up to approximately 7 months

  2. Maximum Observed Plasma Concentration (Cmax) of XB371, Total Antibody and Unconjugated Belotecan

    Time frame: Up to approximately 7 months

  3. Time to Maximum Observed Plasma Concentration (Tmax) of XB371, Total Antibody and Unconjugated Belotecan

    Time frame: Up to approximately 7 months

  4. Trough Observed Plasma Concentration (Ctrough) of XB371, Total Antibody and Unconjugated Belotecan

    Time frame: Up to approximately 7 months

  5. Number of Participants with Antidrug Antibodies to XB371

    Time frame: Up to approximately 7 months

  6. Dose-escalation Cohorts Only: Recommended Dose(s) for Expansion

    Time frame: Through completion of dose-escalation (up to approximately 18 months)

  7. Dose-expansion Cohorts Only: Objective Response Rate as Assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Up to approximately 18 months

  8. Dose-expansion Cohorts Only: Duration of Response as Assessed by the Investigator per RECIST v1.1

    Time frame: Up to approximately 18 months

07

Study locations

10 of 10 sites recruiting
  • Exelixis Clinical Site #5
    Rogers, Arkansas 72758, United States
    Recruiting
  • Exelixis Clinical Site #9
    Los Angeles, California 90033, United States
    Recruiting
  • Exelixis Clinical Site #6
    Washington D.C., District of Columbia 20057, United States
    Recruiting
  • Exelixis Clinical Site #4
    Orlando, Florida 32827, United States
    Recruiting
  • Exelixis Clinical Site #3
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Exelixis Clinical Site #10
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Exelixis Clinical Site #7
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Exelixis Clinical Site #2
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Exelixis Clinical Site #8
    Houston, Texas 77030, United States
    Recruiting
  • Exelixis Clinical Site #1
    San Antonio, Texas 78229, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 14, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Feb 29, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Exelixis Clinical Site #10 · East Brunswick, United States
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added
    Show site
    • Exelixis Clinical Site #10 · East Brunswick, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07123103
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 18, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
1-650-837-7400
Medical Director
study director · Exelixis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion